Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1Phase 2 1

Status

Active not recruiting 6Recruiting 5Terminated 2Completed 2No longer available 1

Sponsor Class

OTHER 23INDUSTRY 5NETWORK 1FED 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Renal Insufficiency 1Prostatic Diseases 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Male Urogenital Diseases 1Genital Neoplasms, Male 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Pluvicto × Clear all
NCT05803941 2026-06-04

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Novartis

Phase 4 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT07226986 2026-06-03

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Novartis

Phase 1/2 Recruiting
123 enrolled
Genitourinary

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT06514521 2026-06-01

Post Marketing Study on Pluvicto in Korea

Novartis

Recruiting
278 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Novartis

Phase 2 Recruiting
20 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡